Optimal infusion rate of remifentanil for maintaining suitable lung compliance in non-muscle relaxant anesthesia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059525

Enrollment

Unknown

Registered

2022-05-03

Start date

2022-06-01

Completion date

Unknown

Last updated

2024-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid nodule, thyroid neoplasms

Interventions

Group A:The infusion rate of remifentanil began with 0.1ug/kg/min

Group B:The infusion rate of remifentanil began with 0.4ug/kg/min

Eligibility

Sex/Gender

All

Age

16 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. In the patients with general anesthesia who underwent selective removal of thyroid disease in our hospital, the study period was January 2022 to March 2023; 2. ASA grade ? - ?, aged 16~50 years, BMI 18.5-23.9.

Exclusion criteria

Exclusion criteria: 1. Patients with cardiopulmonary disease were excluded after preoperative relevant examinations; 2. Patients allergic to various components of this product or other fentanyls; 3. Discontinuation of monoamine oxidase inhibitors for less than 14 days.

Design outcomes

Primary

Measure	Time frame
Pulmonary static compliance;Peak airway pressure;Airway plateau pressure;	—

Countries

China

Contacts

Public ContactSu Zhenbo

suzhenbo2003@163.com+86 13843183340

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026